Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity
Open Access
- 1 January 2013
- journal article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 251
- https://doi.org/10.3389/fimmu.2013.00251
Abstract
Modified vaccinia Ankara (MVA) is a safe and promising viral vaccine vector that is currently investigated in several clinical and pre-clinical trials. In contrast to inactivated or sub-unit vaccines, MVA is able to induce strong humoral as well as cellular immune responses. In order to further improve its CD8 T cell inducing capacity, we genetically adjuvanted MVA with the coding sequence of murine CD40L, a member of the tumor necrosis factor (TNF) superfamily. Immunization of mice with this new vector led to strongly enhanced primary and memory CD8 T cell responses. Concordant with the enhanced CD8 T cell response, we could detect stronger activation of dendritic cells and higher systemic levels of innate cytokines (including IL-12p70) early after immunization. Interestingly, acquisition of memory characteristics (i.e., IL-7R expression) was accelerated after immunization with MVA-CD40L in comparison to non-adjuvanted MVA. Furthermore, the generated CTLs also showed improved functionality as demonstrated by intracellular cytokine staining and in vivo killing activity. Importantly, the superior CTL response after a single MVA-CD40L immunization was able to protect B cell deficient mice against a fatal infection with ectromelia virus. Taken together, we show that genetic adjuvantation of MVA can change strength, quality and functionality of innate and adaptive immune responses. These data should facilitate a rational vaccine design with a focus on rapid induction of large numbers of CD8 T cells able to protect against specific diseases.Keywords
This publication has 82 references indexed in Scilit:
- Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesVaccine, 2012
- Pre-Clinical Efficacy and Safety of Experimental Vaccines Based on Non-Replicating Vaccinia Vectors against Yellow FeverPLOS ONE, 2011
- Vaccine Design for CD8 T Lymphocyte ResponsesCold Spring Harbor Perspectives in Medicine, 2011
- CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primatesNature Medicine, 2011
- The influence of innate and pre‐existing immunity on adenovirus therapyJournal of Cellular Biochemistry, 2009
- Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral InfectionScience, 2009
- IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccineExpert Review of Vaccines, 2009
- HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsPublished by American Society of Hematology ,2006
- Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human CytomegalovirusJournal of Virology, 2004
- [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].1978